Search - tctmd.com

Displaying 1 - 20 of 84

Sort: Relevancy | Date

News Daily News

尽管没有随机对照试验，但倾向得分匹配分析为导管室选择坎格雷洛和GPI提供了指导

Yael L. Maxwell

December 06, 2016

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

Presentation

Timing of Clopidogrel Loading in US Practice

Presenter: Gregg W. Stone

February 08, 2016

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Daily News

在PCI患者中切入部位和坎格雷洛之间没有相互作用

Caitlin E. Cox

October 06, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

News Daily News

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

L.A. McKeown

September 21, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

L.A. McKeown

September 21, 2015

Presentation

Post-ESC_15 Late-Breaking Trial Webcast: MATRIX Duration, OPTIDUAL, and PLATFORM

Presenter: Gregg W. Stone

September 15, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Daily News

La Aprobación de la FDA de Cangrelor Amplía las Opciones Antiplaquetarias para la PCI

Todd Neale

June 29, 2015

News Daily News

FDA 批准坎格雷洛作为 PCI 的抗血小板治疗方案

Todd Neale

June 29, 2015

News Daily News

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Todd Neale

June 29, 2015

Presentation Fellows 2015

Antiplatelet Therapy for the Interventionalist

Presenter: Manish A. Parikh, Roxana Mehran, Gregg W. Stone

May 15, 2015

Presentation

ACC 2015 Late Breaking Trials: PCI Access and Anticoagulation Trials

Presenter: Gregg W. Stone

April 14, 2015

News Daily News

元分析解释了不同DAPT时间长短的影响

Caitlin E. Cox

April 03, 2015

Advertisement

尽管没有随机对照试验，但倾向得分匹配分析为导管室选择坎格雷洛和GPI提供了指导

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Timing of Clopidogrel Loading in US Practice

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

在PCI患者中切入部位和坎格雷洛之间没有相互作用

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

Post-ESC_15 Late-Breaking Trial Webcast: MATRIX Duration, OPTIDUAL, and PLATFORM

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

La Aprobación de la FDA de Cangrelor Amplía las Opciones Antiplaquetarias para la PCI

FDA 批准坎格雷洛作为 PCI 的抗血小板治疗方案

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Antiplatelet Therapy for the Interventionalist

ACC 2015 Late Breaking Trials: PCI Access and Anticoagulation Trials

元分析解释了不同DAPT时间长短的影响

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content